ClinicalTrials.gg
Active, not recruitingNCT07218029SOTERIAUpdated Oct 8, 2026

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

A Phase 3 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 137 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled May 2021, registered Oct 2025).
Updated Oct 8, 2026Now Active, not recruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
815
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Planned enrollment
Largest of 18
815 · median 44
Started
2021
with 2 others
Phase 3
5 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
7 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one has the largest planned enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 14th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse.

Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH.

This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.

Read the detailed description

LTFU PAH sotatercept study MK-7962-004 (Obsolete Identifier: NCT04796337) has been incorporated into the current MK-7962-038 (NCT07218029) study for administrative reasons. The MK-7962-004 study is no longer enrolling participants and will be formally closed. Only those who participated in MK-7962-004 may be eligible to continue into MK-7962-038.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has completed their current respective PAH sotatercept clinical study and its requirements, and must not have discontinued early
  • Is willing to adhere to the study visit schedule, and understands and will comply with all protocol requirements
  • Must have the ability to understand and provide documented

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Did not participate in a sotatercept PAH parent study
  • Missed more than the equivalent of 4 consecutive doses between the end of parent study and the start of this study.
  • Presence of an ongoing serious adverse event that occurred during a PAH sotatercept clinical study that is assessed to be possibly or probably related to sotatercept
  • Is a female who is pregnant or breastfeeding
  • Is or has an immediate family member who is site or Sponsor staff directly involved with this study
  • Is currently enrolled in another investigational product study other than a sotatercept study
  • Is incapacitated
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
815 participants (estimated)

Study arms

  • Experimental
    Sotatercept

    Participants enrolling from blinded PAH sotatercept studies will begin sotatercept at a dose of 0.3 mg/kg subcutaneous (SC) injection and can titrate up to the target dose of 0.7 mg/kg SC injection for the remainder of the study. Participants enrolling from unblinded PAH sotatercept studies will continue sotatercept at their current dose and, if at a dose \<0.7 mg/kg, can titrate up to the target dose of 0.7 mg/kg SC injection for the remainder of the study.

    Biological: Sotatercept

Interventions

  • BiologicalSotatercept

    Sotatercept SC injection every 3 weeks

    Also known as: MK-7962, ACE-011, ActRIIA-IgG1Fc, WINREVAIR®

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 90 months

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 86 months

  3. Number of Participants with Detectable Anti-Drug Antibodies (ADAs)

    ADAs will be detected in serum. The number of participants with detectable ADAs will be reported.

    Time frame: Up to approximately 88 months

  4. Laboratory parameters (Hematology): Concentration of Platelets and Hemoglobin

    Blood samples will be collected to determine the concentration of platelets and hemoglobin.

    Time frame: Up to approximately 88 months

  5. Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT)

    Blood samples will be collected to determine the concentration of creatinine, total bilirubin, and ALT.

    Time frame: Up to approximately 86 months

  6. Change From Baseline in Body Weight

    Change from baseline in body weight will be reported.

    Time frame: Baseline and up to approximately 86 months

  7. Change From Baseline in Blood Pressure

    Change from baseline in systolic and diastolic blood pressure will be reported.

    Time frame: Baseline and up to approximately 86 months

  8. Change From Baseline in Electrocardiogram (ECG)

    Change from baseline in ECG (12-lead) for the determination of Fridericia's corrected QT interval (QTcF) will be reported.

    Time frame: Baseline and up to approximately 86 months

Secondary outcomes

  1. Change From Baseline in 6-Minute Walk Distance (6MWD)

    The 6MWD is the distance walked in 6 minutes as a measure of functional capacity. The change from baseline in 6MWD will be reported.

    Time frame: Baseline and up to approximately 48 months

  2. Change From Baseline in N-Terminal Pro-Hormone B-type Natriuretic Peptide (NT-proBNP) Levels

    NT-proBNP is a circulating biomarker that reflects myocardial stretch. The change from baseline in NT-proBNP levels will be reported.

    Time frame: Baseline and up to approximately 48 months

  3. Change From Baseline in the Percentage of Participants Who Improve or Show Maintenance in Modified New York Heart Association/ World Health Organization Classification of Functional Status (WHO FC)

    The severity of participant's PAH symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform physical activity without any symptoms, dyspnea at rest). Participants will be classified as "Improved", "No change", or "Worsened". Improved = reduction in WHO FC; No Change = no change in WHO FC; Worsened = increase in WHO FC. The change from baseline in the percentage of participants who improve or show maintenance in WHO FC will be reported.

    Time frame: Baseline and up to approximately 48 months

  4. Change From Baseline in Pulmonary Vascular Resistance (PVR)

    PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization. The change from baseline in PVR will be reported.

    Time frame: Baseline and up to approximately 48 months

  5. Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator

    The simplified French Risk scoring system is based on the 2015 European Society of Cardiology/European Respiratory Society guidelines for the diagnosis and treatment of pulmonary hypertension (PH). Noninvasive parameters (WHO FC, 6MWD, NT-proBNP levels) will be used to determine the score. 'Low risk' is defined as maintaining or achieving all 3 low-risk criteria: WHO FC I or II, 6MWD \>440 meters, and NT-proBNP \<300 ng/L. The change from baseline in percentage of participants who maintain or achieve a low risk simplified French Risk score will be reported.

    Time frame: Baseline and up to approximately 48 months

07

Study locations

137 sites

Showing the first 100 of 137 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Humbert M, McLaughlin VV, Waxman AB, Manimaran S, Mikhailova E, Reddy M, Lau A, de Oliveira Pena J, Souza R. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025 Jul 24;66(1):2401435. doi: 10.1183/13993003.01435-2024. Print 2025 Jul. PubMed 39978862 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2028, 90 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's planned 90 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2025
First posted
Oct 20, 2025
StartActual
May 12, 2021
Primary completionEst.
Dec 7, 2028
CompletionEst.
Dec 7, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 8, 2026
Sites
The Emory Clinic ( Site 1030) is now Active, not recruiting
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Emory Clinic ( Site 1030) · Atlanta, United StatesContact removed •••8204
Oct 1, 2026
Show all 2 updates
  1. Oct 8, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details
  2. Oct 1, 2026
    The Emory Clinic ( Site 1030) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Emory Clinic ( Site 1030) · Atlanta, United StatesContact removed •••8204

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07218029
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
May 12, 2021
Primary completion
Dec 7, 2028 (estimated)
Completion
Dec 7, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion